Cancerous
microvesicles (MVs), which are heterogeneous membrane-bound
nanovesicles shed from the surfaces of cancer cells into the extracellular
environment, have been widely recognized as promising “biofingerprints”
for various cancers. High-performance identification of cancerous
MVs plays a vital role in the early diagnosis of cancer, yet it is
still technically challenging. Herein, we report a gold nanoparticle
(AuNP)-decorated, dual-aptamer modified reduced graphene oxide (RGO)
field-effect transistor (AAP-GFET) nanosensor for the label-free,
specific, and sensitive quantification of HepG2 cell-derived MVs (HepG2-MVs).
After GFET chips were fabricated, AuNPs were then decorated on the
RGO surface. For specific capture and detection of HepG2-MVs, both
sulfhydrylated HepG2 cell specific TLS11a aptamer (AptTLS11a) and epithelial cell adhesion molecule aptamer (AptEpCAM) were immobilized on the AuNP surface through an Au–S bond.
This developed nanosensor delivered a broad linear dynamic range from
6 × 105 to 6 × 109 particles/mL and
achieved a high sensitivity of 84 particles/μL for HepG2-MVs
detection. Moreover, this AAP-GFET platform was able to distinguish
HepG2-MVs from other liver cancer-related serum proteins (such as
AFP and CEA) and MVs derived from human normal cells and other cancer
cells of lung, pancreas, and prostate, suggesting its excellent method
specificity. Compared with those modified with a single type of aptamer
alone (AptTLS11a or AptEpCAM), such an AAP-GFET
nanosensor showed greatly enhanced signals, suggesting that the dual-aptamer-based
bio–nano interface was uniquely designed and could realize
more sensitive quantification of HepG2-MVs. Using this platform to
detect HepG2-MVs in clinical blood samples, we found that there were
significant differences between healthy controls and hepatocellular
carcinoma (HCC) patients, indicating its great potential in early
HCC diagnosis.